Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2016

9 - 12 Jun 2016

The Bella Center, Copenhagen, Denmark

Cured AML patients generate anti-tumour antibodies that kill AML blasts

Dr Mette Hazenberg - Academic Medical Center, Amsterdam, The Netherlands

Cured AML patients generate anti-tumour antibodies that kill AML blasts ( Dr Mette Hazenberg - Academic Medical Center, Amsterdam, The Netherlands )

Very late relapse in Hodgkins lymphoma

Dr Paul Bröckelmann - University Hospital of Cologne, Cologne, Germany

Very late relapse in Hodgkins lymphoma ( Dr Paul Bröckelmann - University Hospital of Cologne, Cologne, Germany )

Modelling ponatinib resistance in BCR-ABL1 cell lines

Dr Liu Lu - South Australian Health and Medical Research Institute, Adelaide, Australia

Modelling ponatinib resistance in BCR-ABL1 cell lines ( Dr Liu Lu - South Australian Health and Medical Research Institute, Adelaide, Australia )

Results from the EURO-SKI cessation trial of TKIs in CML

Dr Johan Richter - Lund University, Lund, Sweden

Results from the EURO-SKI cessation trial of TKIs in CML ( Dr Johan Richter - Lund University, Lund, Sweden )

Mutations associated with imatinib response in CML

Katerina Machova Polakova - Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Mutations associated with imatinib response in CML ( Katerina Machova Polakova - Institute of Hematology and Blood Transfusion, Prague, Czech Republic )

CD19 CAR T-cells effective with with low dose chemotherapy.

Dr Stephanie Goff - National Cancer Institute, Bethesda, USA

CD19 CAR T-cells effective with with low dose chemotherapy. ( Dr Stephanie Goff - National Cancer Institute, Bethesda, USA )

Specific mutations in leukaemia patients' blood predicts survival

Dr Klaus Metzeler - University of Munich, Munich, Germany

Specific mutations in leukaemia patients' blood predicts survival ( Dr Klaus Metzeler - University of Munich, Munich, Germany )

Causes and consequences of microRNA dysregulation in cancer

Prof Carlo Croce - Ohio State University, Columbus, USA

Causes and consequences of microRNA dysregulation in cancer ( Prof Carlo Croce - Ohio State University, Columbus, USA )

Sequencing multiple myeloma reveals a complex landscape of genetic lesions

Dr Niccolo Bolli - University of Milan, Milan, Italy

Sequencing multiple myeloma reveals a complex landscape of genetic lesions ( Dr Niccolo Bolli - University of Milan, Milan, Italy )

Results from SCHOLAR-1 trial for DLBCL patients

Prof Christian Gisselbrecht - LYSARC, Pierre-Bénite, France

Results from SCHOLAR-1 trial for DLBCL patients ( Prof Christian Gisselbrecht - LYSARC, Pierre-Bénite, France )

Super-enhancer analysis reveals subtypes in AML and MDS

Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA

Super-enhancer analysis reveals subtypes in AML and MDS ( Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA )

PD-1 enhances elotuzumab efficacy

Dr Natalie Bezman - Bristol-Meyers Squibb, Princeton, USA

PD-1 enhances elotuzumab efficacy ( Dr Natalie Bezman - Bristol-Meyers Squibb, Princeton, USA )

Novel therapies for older patients with AML and MDS

Prof Naval Daver - MD Anderson Cancer Center, Houston, United States

Novel therapies for older patients with AML and MDS ( Prof Naval Daver - MD Anderson Cancer Center, Houston, United States )

Better screening programmes needed for haematological malignancies such as leukaemia

Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany

Better screening programmes needed for haematological malignancies such as leukaemia ( Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany )

Karyotyping a CLL subset with ibrutinib susceptibility

Dr Jeffrey Jones - Ohio State University, Columbus, USA

Karyotyping a CLL subset with ibrutinib susceptibility ( Dr Jeffrey Jones - Ohio State University, Columbus, USA )

Chemo-genomic interrogation reveals JAK sensitive subgroup in AML

Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada

Chemo-genomic interrogation reveals JAK sensitive subgroup in AML ( Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada )

The role of AKT in chronic lymphocytic leukaemia transformation to Richter's syndrome

Dr Christian Pallasch, University Hospital of Cologne, Cologne, Germany

The role of AKT in chronic lymphocytic leukaemia transformation to Richter's syndrome ( Dr Christian Pallasch, University Hospital of Cologne, Cologne, Germany )

Advances in first line treatment options for MCL patients

Professor Steven Le Gouill and Professor Simon Rule

Advances in first line treatment options for MCL patients ( Professor Steven Le Gouill and Professor Simon Rule )

Targeted genome editing in haematopoeitic stem cells

Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy

Targeted genome editing in haematopoeitic stem cells ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )

A microRNA driver of B-cell leukaemia

Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy

A microRNA driver of B-cell leukaemia ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )

The latest in CLL from EHA 2016

Prof Peter Hillmen, Prof Paolo Ghia, Dr Chris Fox and Dr Constantine Tam

The latest in CLL from EHA 2016 ( Prof Peter Hillmen, Prof Paolo Ghia, Dr Chris Fox and Dr Constantine Tam )

Safety and efficacy of imatinib generics

Prof Tomasz Sacha - Jagiellonian University, Krakow, Poland

Safety and efficacy of imatinib generics ( Prof Tomasz Sacha - Jagiellonian University, Krakow, Poland )

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo

Dr Amir Fathi, Massachusetts General Hospital, Boston, USA

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo ( Dr Amir Fathi, Massachusetts General Hospital, Boston, USA )

Meta-analysis of overall survival in multiple myeloma treated with lenalidomide

Dr Philip McCarthy - Roswell Park Cancer Institute, New York, USA

Meta-analysis of overall survival in multiple myeloma treated with lenalidomide ( Dr Philip McCarthy - Roswell Park Cancer Institute, New York, USA )

Risk adapted therapy for acute myeloid leukaemia

Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain

Risk adapted therapy for acute myeloid leukaemia ( Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain )

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients

Dr Emmanuelle Tchernonog - CHRU Montpellier, Montpellier, France

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients ( Dr Emmanuelle Tchernonog - CHRU Montpellier, Montpellier, France )

Blinatumomab improves survival of relapsed B-cell leukaemia

Prof Max Topp - University of Würzburg, Würzburg, Germany

Blinatumomab improves survival of relapsed B-cell leukaemia ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Decoding the risk of thromboembolic events in lymphoma patients

Prof Darko Antic - Clinic For Hematology, Clinical Center Serbia, Belgrade, Serbia

Decoding the risk of thromboembolic events in lymphoma patients ( Prof Darko Antic - Clinic For Hematology, Clinical Center Serbia, Belgrade, Serbia )

SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML

Dr Amir Fathi - Massachusetts General Hospital, Boston, USA

SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML ( Dr Amir Fathi - Massachusetts General Hospital, Boston, USA )

Killer antibodies against AML

Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands

Killer antibodies against AML ( Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands )

Improved survival in adult ALL

Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark

Improved survival in adult ALL ( Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark )

Multiple myeloma highlights from EHA 2016

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy

Multiple myeloma highlights from EHA 2016 ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy )

Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia

Dr Charles De Bock - KU Leuven, Leuven, Belgium

Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia ( Dr Charles De Bock - KU Leuven, Leuven, Belgium )

SL401 in patients with rare neoplasm

Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houston, United States

SL401 in patients with rare neoplasm ( Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houston, United States )

RNA regulation of JAK-STAT pathways in CML

Prof Danilo Perrotti - The University of Maryland Baltimore, Baltimore, USA

RNA regulation of JAK-STAT pathways in CML ( Prof Danilo Perrotti - The University of Maryland Baltimore, Baltimore, USA )

Daratumumab shows remarkable benefit in relapsed or refractory MM

Prof Meletios Dimopoulos - University Athens School of Medicine, Athens, Greece

$Daratumumab shows remarkable benefit in relapsed or refractory MM ( Prof Meletios Dimopoulos - University Athens School of Medicine, Athens, Greece )$

Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence

Dr Klaus Metzeler - Ludwig-Maximilians-Universität, Munich, Germany

Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence ( Dr Klaus Metzeler - Ludwig-Maximilians-Universität, Munich, Germany )

Blinatumomab improves survival in ALL patients

Prof Max Topp - University of Würzburg, Würzburg, Germany

Blinatumomab improves survival in ALL patients ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Stopping tyrosine kinase inhibitors in CML

Dr Johan Richter - Lund University, Sweden

Stopping tyrosine kinase inhibitors in CML ( Dr Johan Richter - Lund University, Sweden )

Evaluation of ibrutinib in treatment of CLL with 17p deletion

Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA

Evaluation of ibrutinib in treatment of CLL with 17p deletion ( Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA )

Nivolumab restores effective anti-tumour response in Hodgkin lymphoma

Dr Anas Younes - Memorial Sloan Kettering Cancer Centre, New York, USA

Nivolumab restores effective anti-tumour response in Hodgkin lymphoma ( Dr Anas Younes - Memorial Sloan Kettering Cancer Centre, New York, USA )

An overview of MCL from EHA 2016

Professor Simon Rule and Professor Steven Le Gouill

An overview of MCL from EHA 2016 ( Professor Simon Rule and Professor Steven Le Gouill )

More from ecancer